|
| 37269078 | Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. | Clin Trials | 2024 |
| 38086517 | Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods. | J Am Acad Dermatol | 2024 |
| 37904489 | Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. | Clin Trials | 2024 |
| 37950060 | Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution. | Skeletal Radiol | 2024 |
| 36057449 | Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas. | NMR Biomed | 2023 |
| 37354152 | A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas. | J Invest Dermatol | 2023 |
| 37321378 | CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas. | Magn Reson Imaging | 2023 |
| 37318402 | Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1. | J Invest Dermatol | 2023 |
| 37253707 | Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy. | J Pediatr Orthop | 2023 |
| 37149083 | cNF-Skindex in Adults Living with Neurofibromatosis 1: Severity Strata in France and Validation in United States Adults. | J Invest Dermatol | 2023 |
| 37115514 | Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. | Neuro Oncol | 2023 |
| 37382607 | Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors. | Clin Cancer Res | 2023 |
| 37245145 | RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights. | J Invest Dermatol | 2023 |
| 37010875 | Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. | Neuro Oncol | 2023 |
| 37437149 | Precision Oncology for Papillary Craniopharyngioma. | N Engl J Med | 2023 |
| 37330719 | Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas. | J Invest Dermatol | 2023 |
| 37330718 | Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas. | J Invest Dermatol | 2023 |
| 37294242 | Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas. | J Invest Dermatol | 2023 |
| 36651958 | Occurrence and Severity of Suicidal Ideation in Adults With Neurofibromatosis Participating in a Mind-Body RCT. | Cogn Behav Neurol | 2023 |
| 36840626 | Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. | Neuro Oncol | 2023 |
| 36565307 | COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. | Genet Med | 2023 |
| 34898238 | Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. | J Clin Oncol | 2022 |
| 35740680 | Therapeutic Vulnerability to ATR Inhibition in Concurrent <i>NF1</i> and <i>ATRX</i>-Deficient/ALT-Positive High-Grade Solid Tumors. | Cancers (Basel) | 2022 |
| 35511749 | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Mol Cancer Ther | 2022 |
| 35678462 | Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. | Am J Med Genet A | 2022 |
| 35674741 | Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. | Genet Med | 2022 |
| 35467749 | Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. | Neuro Oncol | 2022 |
| 35788692 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. | Neuro Oncol | 2022 |
| 35452155 | Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. | Magn Reson Med | 2022 |
| 35657359 | Management of neurofibromatosis type 1-associated plexiform neurofibromas. | Neuro Oncol | 2022 |
| 35905666 | Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. | Neuroimage Clin | 2022 |
| 36069570 | Natural History of Brachial Plexus, Peripheral Nerve, and Spinal Schwannomas. | Neurosurgery | 2022 |
| 35244537 | Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. | Elife | 2022 |
| 33025139 | Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Acta Neuropathol | 2021 |
| 33507822 | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. | J Clin Oncol | 2021 |
| 34667843 | Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. | Laryngoscope Investig Otolaryngol | 2021 |
| 34806136 | Brain Cancers in Genetic Syndromes. | Curr Neurol Neurosci Rep | 2021 |
| 34224367 | Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. | Mol Cancer Ther | 2021 |
| 34277020 | Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. | Neurooncol Pract | 2021 |
| 34012067 | Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. | Genet Med | 2021 |
| 34264955 | Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. | PLoS One | 2021 |
| 34233941 | Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. | Neurology | 2021 |
| 34230202 | Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials. | Neurology | 2021 |
| 34230200 | Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment. | Neurology | 2021 |
| 34230199 | Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. | Neurology | 2021 |
| 34230197 | Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. | Neurology | 2021 |
| 34230196 | Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. | Neurology | 2021 |
| 33112994 | Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. | Acta Neuropathol | 2021 |
| 30963251 | An update on the central nervous system manifestations of neurofibromatosis type 1. | Acta Neuropathol | 2020 |
| 33506200 | Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. | Neurooncol Adv | 2020 |